The FDA on February 11, 2025, approved ADCETRIS® in combination with Lenalidomide and a Rituximab product for adult patients with relapsed or refractory Large B-Cell Lymphoma (LBCL), including Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or High-Grade B-Cell Lymphoma (HGBL), after two or more lines of systemic therapy, who are ineligible for autologous Hematopoietic Stem Cell Transplantation (auto-HSCT) or CAR T-cell therapy. ADCETRIS® is a product of Seagen Inc., a subsidiary of Pfizer.
Bottom Ad
Advertisement
Subscribe
